Ads
related to: thromboxane a synthase blood test
Search results
Results From The WOW.Com Content Network
The human thromboxane A (TXA) synthase is a 60 kDa cytochrome P450 protein with 533 amino acids and a heme prosthetic group.This enzyme, anchored to the endoplasmic reticulum, is found in platelets, monocytes, and several other cell types.
A decrease in Thromboxane-A synthase leads to an increase in prostaglandin E2 levels which may affect erythroid precursor cells by suppressing them which likely leads to refractory anemia. [ 15 ] There are still unanswered questions about the effect of a compromised TBXAS1 gene function and its affect in Ghosal hematodiaphyseal dysplasia.
Thromboxane A 2 (TXA 2) is generated from prostaglandin H 2 by thromboxane-A synthase in a metabolic reaction which generates approximately equal amounts of 12-hydroxyheptadecatrienoic acid (12-HHT). Aspirin irreversibly inhibits platelet cyclooxygenase 1 preventing the formation of prostaglandin H 2, and therefore TXA 2.
Thromboxane synthase inhibitors inhibit the final enzyme (thromboxane synthase) in the synthesis of thromboxane. Ifetroban is a potent and selective thromboxane receptor antagonist. [10] Dipyridamole antagonizes this receptor too, but has various other mechanisms of antiplatelet activity as well.
Thromboxane A2 (TX2) has a positive feedback in platelet activation. It is produced by the oxygenation of arachidonic acid by two enzymes: cycloxygenase and thromboxane A2 synthase. TX2 effects are mediated by G protein-coupled receptors, subtypes TPα and TPβ.
The thromboxane receptor (TP) also known as the prostanoid TP receptor is a protein that in humans is encoded by the TBXA2R gene, The thromboxane receptor is one among the five classes of prostanoid receptors [5] and was the first eicosanoid receptor cloned. [6] The TP receptor derives its name from its preferred endogenous ligand thromboxane A ...
Furegrelate is able to bind to the enzyme thromboxane A2 synthase. By binding to thromboxane A2 synthase it negates the effects and prevents it from acting like a vasoconstrictor. Because of this Furegrelate is capable of preventing several diseases involving thrombosis, the occurrence of blood clots that block veins or arteries. Furegrelate is ...
Thromboxanes are responsible for the aggregation of platelets that form blood clots. [12] Low-dose, long-term aspirin use irreversibly blocks the formation of thromboxane A 2 in platelets, producing an inhibitory effect on platelet aggregation. [13]